Nutriband (Nutriband) Gross-Profit-to-Asset % : 9.03% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nutriband Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nutriband's annualized Gross Profit for the quarter that ended in Jan. 2024 was $0.72 Mil. Nutriband's average Total Assets over the quarter that ended in Jan. 2024 was $8.02 Mil. Therefore, Nutriband's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2024 was 9.03%.

Nutriband Gross-Profit-to-Asset % Historical Data

The historical data trend for Nutriband's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Gross-Profit-to-Asset % Chart

Nutriband Annual Data

Trend

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-7.11

5.21

4.45

6.76

10.16

Nutriband Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															5.13	9.79	12.94	6.91	9.03

Competitive Comparison of Nutriband's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Nutriband's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutriband's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nutriband's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nutriband's Gross-Profit-to-Asset % falls into.

Nutriband Gross-Profit-to-Asset % Calculation

Nutriband's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jan. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jan. 2024 )	/	( (Total Assets (A: Jan. 2023 )	+	Total Assets (A: Jan. 2024 ))	/ count )
	=	0.862	/	( (9.456	+	7.517)	/ 2 )
	=	0.862	/	8.4865
	=	10.16 %

Nutriband's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jan. 2024 )	/	( (Total Assets (Q: Oct. 2023 )	+	Total Assets (Q: Jan. 2024 ))	/ count )
	=	0.724	/	( (8.523	+	7.517)	/ 2 )
	=	0.724	/	8.02
	=	9.03 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jan. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Nutriband Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nutriband's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

9WV:Germany

Address

121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801

Website

https://www.nutriband.com

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Executives

Michael Davidov	director	60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik	director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan	director, 10 percent owner, officer: CEO	6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros	director, 10 percent owner, officer: Chairman of the BOD	GREGERSTR 36B, FISHAMEND C4 2401